[Evaluation of the therapeutic action of hexosephosphate as an energy-supplying agent in acute coronary insufficiency].
It was established in experiments on 24 dogs with ligated interventricular branch of the left coronary artery that hexosophosphate (0.5 and 1 ml/kg intravenously) increases the collateral coronary blood flow and myocardial contractility against the background of a decrease in the lactate content in blood draining from the ischemic zone. Preliminary injection of hexosophosphate to rabbits increases the respiratory control in mitochondria from the ischemic myocardium. Drip intravenous hexosophosphate (100 ml) infusion to patients in the acute period of myocardial infarction reduced significantly sigma ST in precardiac leads and reduced the lactic acid content in venous blood. In 7.6% of cases hexosophosphate caused arrest or abatement of the pain syndrome.
D000208:Acute Disease; D000368:Aged; D000818:Animals; D003097:Collateral Circulation / Q000187:drug effects; D003327:Coronary Disease / Q000188:drug therapy*; D004285:Dogs; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D004734:Energy Metabolism / Q000187:drug effects*; D005260:Female; D006321:Heart / Q000187:drug effects; D006600:Hexosephosphates / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy; D009206:Myocardium / Q000378:metabolism; D011817:Rabbits; D013997:Time Factors
D006600:Hexosephosphates
Otsenka lechebnogo deĭstviia geksozofosfata kak énergoobespechivaiushchego sredstva pri ostroĭ koronarnoĭ nedostatochnosti.